Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katerina Hrochova"'
Publikováno v:
Leukemia Research Reports, Vol 18, Iss , Pp 100346- (2022)
GATA2 deficiency was first identified in 2011 and have been reported over 500 individuals with GATA2 mutations. The onset of symptoms ranges from early childhood to late adulthood but very often the diagnosis is made between adolescence and early adu
Externí odkaz:
https://doaj.org/article/23a0307ae26845b4ac74e87e5281183c
Autor:
Petra Belohlavkova, Filip Vrbacky, Jaroslava Voglova, Zdenek Racil, Daniela Zackova, Katerina Hrochova, Jana Malakova, Jiri Mayer, Pavel Zak
Publikováno v:
Archives of Medical Science, Vol 14, Iss 6, Pp 1416-1423 (2018)
Externí odkaz:
https://doaj.org/article/602ee88bf1304c86809033b0d80e72f9
Publikováno v:
Clinical Biochemistry. 61:34-39
Objectives Molecular screening plays a major role in prognostic categorization and subsequent definition of treatment strategies for acute myeloid leukemia. The possibility of using IDH1/2 mutations as a marker for the monitoring of minimal residual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::492cfff763591a0d0bff1cdc9aedf810
https://doi.org/10.1016/j.clinbiochem.2018.08.012
https://doi.org/10.1016/j.clinbiochem.2018.08.012
Autor:
Jan Laco, Ema Ruszova, Katerina Hrochova, Ivana Baranova, Marcela Chmelarova, Vladimir Palicka, Eva Dvorakova
Publikováno v:
Pathology & Oncology Research. 25:1457-1465
Epigenetic aberrations are well known to play an important role in carcinogenesis, and also have a great potential to serve as biomarkers in many types of cancers, including ovarian cancer in which sensitive and specific biomarkers and detection meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b2fe05c195486f042d3df36443d156
https://doi.org/10.1007/s12253-018-0500-y
https://doi.org/10.1007/s12253-018-0500-y
Autor:
Daniela Zackova, Jiri Mayer, Petra Belohlavkova, Jana Malakova, Katerina Hrochova, Zdenek Racil, Jaroslava Voglová, Pavel Zak, Filip Vrbacky
Publikováno v:
Archives of Medical Science, Vol 14, Iss 6, Pp 1416-1423 (2018)
Archives of Medical Science : AMS
Archives of Medical Science : AMS
Introduction: Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes. Material and methods: In the present study we evaluated the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a63ab0c38121d1e77a230d657d6e5cf
https://www.termedia.pl/The-significance-of-enzyme-and-transporter-polymorphisms-for-imatinib-plasma-levels-and-achieving-an-optimal-response-in-chronic-myeloid-leukemia-patients,19,31830,1,1.html
https://www.termedia.pl/The-significance-of-enzyme-and-transporter-polymorphisms-for-imatinib-plasma-levels-and-achieving-an-optimal-response-in-chronic-myeloid-leukemia-patients,19,31830,1,1.html
Autor:
Eva Dvorakova, Ema Ruszova, Jiri Spacek, Spela Kos, Vladimir Palicka, Katerina Hrochova, Jan Laco, Marcela Chmelarova
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 52
BACKGROUND Epigenetic changes are considered to be a frequent event during tumor development. Various methylation changes have been identified and show promise as potential cancer biomarkers. The aim of this study was to investigate promoter methylat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2582fb88cb5299e9732011972c8b5714
https://doi.org/10.1515/cclm-2013-0162
https://doi.org/10.1515/cclm-2013-0162